Aligos Therapeutics, Inc. Common Stock (ALGS) Stock Price

ALGSStock

$7.47−32.06%52W

Market Cap$46.65M

P/E—

PEG Ratio—

Div yield—

Beta2.43

ALGS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.33%

Price vs S&P 500 (4W)60.01%

VGM Score67.93

Book Value / Share (Quarterly)$5.14

P/TBV (Annual)0.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-46.04%

Cash Flow / Share (Quarterly)$-13.77

Price vs S&P 500 (YTD)-37.60%

Net Profit Margin (TTM)-1919.68%

EPS (TTM)$-8.70

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-8.70

EPS (Annual)$-2.45

ROI (Annual)-45.06%

Net Profit Margin (5Y Avg)-1726.24%

Cash / Share (Quarterly)$8.87

Revenue Growth QoQ (YoY)809.97%

ROA (Last FY)-27.33%

Revenue Growth TTM (YoY)43.88%

EBITD / Share (TTM)$-9.11

ROE (5Y Avg)-70.33%

Operating Margin (TTM)-2033.39%

Cash Flow / Share (Annual)$-13.42

P/B Ratio1.33x

P/B Ratio (Quarterly)1.45x

Net Income / Employee (Annual)$-295,000

EV / Revenue (TTM)2.63x

ROA (TTM)-90.88%

EPS Incl Extra (Annual)$-2.45

Current Ratio (Annual)3.90x

Quick Ratio (Quarterly)2.56x

3-Month Avg Trading Volume0.24M

52-Week Price Return-32.06%

Revenue / Employee (TTM)$57,400

Tangible BV / Share (Quarterly)$1.26

P/S Ratio (Annual)19.34x

Asset Turnover (Annual)0.02x

52-Week High$13.69

Operating Margin (5Y Avg)-2099.40%

EPS Excl Extra (Annual)$-2.45

CapEx CAGR (5Y)-26.66%

26-Week Price Return1.91%

Quick Ratio (Annual)3.90x

13-Week Price Return21.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.56x

Enterprise Value$12.38M

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$26,700

Pretax Margin (Annual)-1092.36%

Cash / Share (Annual)$12.60

3-Month Return Std Dev105.52%

Net Income / Employee (TTM)$-1,101,500

ROE (Last FY)-45.18%

EPS Basic Excl Extra (Annual)$-2.45

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-8.70

ROI (TTM)-139.19%

P/S Ratio (TTM)8.99x

Pretax Margin (5Y Avg)-1719.87%

Revenue / Share (Annual)$0.22

Tangible BV / Share (Annual)$2.42

Price vs S&P 500 (52W)-50.37%

Year-to-Date Return-25.64%

5-Day Price Return2.51%

EPS Normalized (Annual)$-2.45

ROA (5Y Avg)-78.47%

Net Profit Margin (Annual)-1106.72%

Month-to-Date Return63.83%

Cash Flow / Share (TTM)$-1.86

EBITD / Share (Annual)$-8.81

Operating Margin (Annual)-4024.93%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-70.14%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-8.70

P/TBV (Quarterly)0.98x

P/B Ratio (Annual)1.07x

Pretax Margin (TTM)-1907.18%

Book Value / Share (Annual)$8.67

Price vs S&P 500 (13W)18.57%

Beta2.43x

Revenue / Share (TTM)$0.45

ROE (TTM)-139.47%

52-Week Low$3.98

vGradeB

gGradeA

mGradeC

vgmGradeB

ALGS Earnings Surprise History

Q2 25-1.53est. -2.54

Q3 25-3.04est. -2.01

Q4 25-1.91est. -2.49

Q1 26-2.21est. -2.37

Q2 26-0.14est. -1.38

ALGS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.18

4.15

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALGSAligos Therapeutics, Inc. Common Stock	B	A	C	$7.47
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Aligos Therapeutics, Inc. Common Stock

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, including chronic hepatitis B, coronaviruses, and nonalcoholic steatohepatitis (NASH). The company maintains a pipeline of drug candidates targeting these areas of significant unmet medical need.